Sun Pharma Prices Rs 10,000 Cr Bond Sale to Refinance Organon Deal Bridge Loans
OGN has more than doubled off its 52-week low of $5.69.
Summary
Sun Pharma priced Rs 10,000 crore of rupee bonds in two tranches — Rs 7,000 crore at 8.20% and Rs 3,000 crore at 8.05% with a 2028 put — to partly refinance bridge loans for its $11.75 billion enterprise-value acquisition of Organon. The deal itself is already locked in: Organon shareholders approved the $14.00 per share all-cash buyout with 98.7% of votes in July, so this is financing mechanics rather than new deal risk. Crisil rated the NCDs AAA/Stable, and Sun Pharma plans to fund $2-2.5 billion from cash with the remaining $9.5-10 billion through debt. For Organon holders the takeaway is that the buyer's funding path is progressing on schedule, which supports deal certainty at the agreed $14.00 price — well above the current $13.74 quote.
At the time of this announcement, OGN was trading at $13.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $5.69 to $13.83. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Businessworld.